Literature DB >> 4204790

Vitamin E in angina pectoris.

T W Anderson.   

Abstract

The claim that the symptoms of angina pectoris can usually be relieved by large doses of vitamin E has been reinvestigated by means of a randomized double-blind trial. The trial lasted nine weeks and consisted of two parts. One part was conducted as a regular double-blind trial involving 40 patients, half of whom received 3200 IU of vitamin E daily, while an equal number received an indistinguishable placebo. The second part of the trial involved 15 patients who were already taking a regular daily dose of between 400 and 2400 IU of vitamin E. Eight patients were assigned the same (or a larger) dose of vitamin E, while seven received placebo. Neither part of the trial yielded statistically convincing evidence that vitamin E is of value in the treatment of angina, but a small beneficial effect could not be ruled out. Taken in conjunction with the positive (but statistically non-significant) results obtained in the only other double-blind trial of vitamin E ever carried out on angina, and the encouraging results reported by other investigators in the treatment of intermittent claudication, it is suggested that further double-blind trials are justified.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4204790      PMCID: PMC1947289     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  9 in total

1.  Treatment of intermittent claudication. A reappraisal of the value of alpha-tocopherol.

Authors:  A M BOYD; J MARKS
Journal:  Angiology       Date:  1963-04       Impact factor: 3.619

2.  Vitamin E.

Authors:  A Vogelsang; W E Shute; E V Shute
Journal:  Can Med Assoc J       Date:  1948-12       Impact factor: 8.262

3.  Experience with vitamin E in coronary disease.

Authors:  H P RUSH
Journal:  Calif Med       Date:  1949-12

4.  Vitamin E in arteriosclerotic heart and peripheral vascular disease.

Authors:  M E EISEN; H GROSS
Journal:  N Y State J Med       Date:  1949-10-15

5.  Failure of alpha tocopherol to influence chest pain in patients with heart disease.

Authors:  S H RINZLER; H BAKST
Journal:  Circulation       Date:  1950-02       Impact factor: 29.690

6.  The treatment of peripheral occlusive arterial disease with alpha-tocopherol as compared with vasodilator agents and antiprothrombin (dicumarol).

Authors:  K Haeger
Journal:  Vasc Dis       Date:  1968-12

7.  Twenty-four years using alpha-tocopherol in degenerative cardiovascular disease.

Authors:  A Vogelsang
Journal:  Angiology       Date:  1970-04       Impact factor: 3.619

8.  Alpha tocopherol in the treatment of intermittent claudication.

Authors:  H T Williams; D Fenna; R A Macbeth
Journal:  Surg Gynecol Obstet       Date:  1971-04

9.  Vitamin C and the common cold: a double-blind trial.

Authors:  T W Anderson; D B Reid; G H Beaton
Journal:  Can Med Assoc J       Date:  1972-09-23       Impact factor: 8.262

  9 in total
  6 in total

1.  Vitamin therapy: too much or too little?

Authors:  T W Anderson
Journal:  Can Fam Physician       Date:  1975-04       Impact factor: 3.275

Review 2.  Vitamin E and cardiovascular disease.

Authors:  J Kleijnen; P Knipschild; G ter Riet
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  The effects of vitamin E on serum enzyme levels following heavy exercise.

Authors:  I Helgheim; O Hetland; S Nilsson; F Ingjer; S B Strømme
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1979-03-01

4.  Drug treatment of chronic stable angina pectoris.

Authors: 
Journal:  Br Med J       Date:  1978-02-25

5.  Effects of alpha tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris.

Authors:  J M Rapola; J Virtamo; S Ripatti; J K Haukka; J K Huttunen; D Albanes; P R Taylor; O P Heinonen
Journal:  Heart       Date:  1998-05       Impact factor: 5.994

Review 6.  The role of vitamin E in normal and damaged skin.

Authors:  F Nachbar; H C Korting
Journal:  J Mol Med (Berl)       Date:  1995-01       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.